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Background: Meningiomas are mostly benign tumors which arise from the meninges. They are among the
cytogenetically best-studied solid tumors, mostly displaying a normal karyotype or, as a typical primary aberration,
monosomy of chromosome 22. Further secondary chromosomal aberrations, especially the deletion of chromosome
1p, are correlated with increasing biological aggressiveness up to malignancy. These data are derived from the
cytogenetical characterization of 661 meningiomas, from which the genetic progression score (GPS) has been
developed. Due to the high expenditure of time and the expert knowledge for the cytogenetical characterization,
the aim of this work was to establish an equally reliable yet more rapid clinical diagnosis based on fluorescence
in situ hybridization (FISH) on meningiomas. Thus a comparison between the native tumor tissue and the primary
culture of the same tumor was done in order to determine the most efficient method for a molecular cytogenetic
characterization. The diagnostic procedure has to deliver fast and robust results, since they must enable the
attending physician to plan the appropriate follow-up regimens for the patients. All in all, preparations of native
tumor tissue as well as preparations of cell culture of 22 meningiomas were tested with FISH for aberrations
concerning the prognostically relevant chromosome regions 1p and 9p, and the chromosomes 10, 14, 18 and 22 in
comparison with the particular karyotypes revealed by conventional karyotyping using G-banding.
Results: The FISH examinations between native and cultured cells showed an accordance of 93.4%. The
comparison of FISH data and karyotyping presented accordance to the greatest possible extent concerning the
chromosomes 14, 18 and 22, but to detect the progression associated losses of 1p and 9p FISH is the most
sensitive method.
Conclusions: The raised data reveal that both methods can be used for a significant analysis of chromosome
aberrations on meningiomas. As a result of that the complex primary culture could also be avoided. Therefore a
clinical diagnosis based on FISH on meningiomas is at hand for the assignment of patients to a suitable follow-up
regimen.
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Meningiomas are typically benign and slow-growing tu-
mors arising from arachnoidal cells of the leptomeninges
of brain and spinal cord. They belong to the cytogeneti-
cally best-studied solid tumors with a normal karyotype
or, typically, monosomy of chromosome 22, which was* Correspondence: Steffi.Urbschat@uks.eu
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stated.first mentioned by Zang and Singer in 1967 [1]. The loss
of chromosome 22 [1-3] is followed by clinically relevant
secondary losses of complete chromosomes or parts of
them. The chromosomes 6, 10, 14, 18 and 19 and partial
or complete loss of the short arm of one chromosome 1
or 9 are particularly affected [3-20], whereby increasing
hypodiploidy is strongly correlated with increasing ma-
lignancy. According to a study of 661 meningiomas [11],
more than 75% of meningiomas belong to the common
type (WHO grade I), ~20% belong to the atypical or
intermediate type (WHO grade II) and only ~3% belongLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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5% of all meningiomas, consisting of all anaplastic men-
ingiomas and a minority of the other subtypes, show an
aggressive clinical behaviour with increased risk of tumor
recurrence. However, even low-grade meningiomas ex-
hibit an unexpectedly high recurrence rate [21-33]. To
recognize the patients with the high risk of tumor recur-
rence, Ketter et al. [8] developed a neurosurgeon’s postop-
erative management protocol, which is based on the
cytogenetical data of 661 meningiomas. The raised data of
these cytogenetically characterized meningioma patients,
including 53 patients with tumor recurrence, enable an
application of a new mathematical model, in which the
cancer development is described biomathematically by
mixtures of oncogenetic tree models. The mixture
model proposed by Ketter et al. [9] allows every gen-
etic pattern of a meningioma to be explained, and the
probabilistic framework facilitates for converting pro-
balilities to times and thus assigning a genetic progres-
sion score (GPS) to every tumor sample. So the GPS
allows a better assessment of the prognosis of meningi-
omas than traditional categorical cytogenetic markers
and provides a further relevant discrimination of high
risk and low risk groups within the same WHO grade.
To plan the appropriate follow-up regimens for the pa-
tients, clinical diagnostics have to deliver fast and sig-
nificant results.
The aim of this work was to establish a clinical diag-
nostic procedure, based on fluorescence in situ hy-
bridization (FISH) on meningiomas to determine the
genetic pattern for calculating the GPS. A comparison
between the native tumor tissue and the primary cul-
ture of the same tumor was done in order to determine




Primary cultures plus native tissue samples from 22
meningiomas were established. To calculate the growing
period of the primary culture of meningiomas, the
period between the establishment and the first splitting
of the primary culture was determined. The average
growing time was 17.95 days with the shortest time of 7
days and the longest time of 38 days (Table 1). It should
be noted, however, that the normal range of all primary
cultures is between 7 days and 25 days. Three meningi-
omas fell out of this range, because they showed growing
periods of 31 days, 32 days and 38 days. In addition,
none of these three meningiomas exhibited the typical
monosomy 22. Therefore we had to assume that the pri-
mary cultures with a growing time of about four weeks
showed no tumor cells. Probably the tumor samples
ontained no viable tumor cells.Conventional karyotyping using G-banding
Microscopic karyotyping showed in a total of nine cases
(40.9%) no numerical or structural aberrations. Two fur-
ther cases (9.1%) showed no numerical or structural ab-
errations regarding the chromosomes 1, 9, 10, 14, 18
and 22, but losses of chromosome 3, 4 and X were de-
tected as atypical anomalies. In two cases (9.1%), the
monosomy 22 was the only aberration, and in one case
(4.5%), monosomy 18 in addition to monosomy 22 was
detected. Furthermore, (13.6%) the monosomy 22 was
accompanied by other secondary losses like losses of
chromosome 10, 14, 18 and further atypical chromo-
some aberrations in three cases. One further case
(4.5%) exhibited a complex karyotype containing typ-
ical monosomy 22. In four cases (18.2%), a chromo-
some preparation was not possible. In any karyotyped
cases aberrations regarding the chromosome regions
1p and 9p were not found. In summary the most fre-
quent aberration was monosomy 22 followed by loss of
chromosome 10, 14 and 18 which was observed in 2
cases each (Table 1, Figure 1).
Fluorescence in situ hybridization of the tumor cells
In this study, the examination with FISH in the native
tumor tissue (Figure 1; Table 1) showed in a total of nine
cases (40.9%) no numerical or structural aberrations re-
garding the chromosomal regions 1p36, 9p21, 10q23,
14q24, 18q21 and 22q11. In five cases (22.7%), the
monosomy 22 was the only aberration and in further
five cases (22.7%), the monosomy 22 was accompanied
by other secondary losses. Three meningiomas (13.6%)
showed no aberration concerning chromosome 22, but a
loss of chromosome 1p and 9p in one case each and a
loss of 14 and 18 in the third case.
The cell culture presented in a total of ten cases
(45.5%) no numerical or structural aberrations regarding
the chromosomal regions 1p36, 9p21, 10q23, 14q24,
18q21 and 22q11 using FISH analysis. In six cases
(27.3%), the monosomy 22 was the only aberration, and
in further three cases (13.6%) the monosomy 22 was ac-
companied by other secondary losses. Three meningiomas
(13.6%) showed no aberration concerning chromosome
22, but a loss of chromosome 1, 9 and 14 in one case each
(Figures 1 and 2; Table 1).
In a total of five cases (22.7%), the evaluation of chro-
mosome 10 was not possible concerning the native
tumor tissue as well as the cell culture because of tech-
nical problems. Additionally, in one case, the evaluation
of the chromosomes 1 and 22 and, in one further case,
the evaluation of the chromosomes 9, 10, 14 and 18 was
not possible in the native tumor tissue because of strong
autofluorescence (Table 1).
In summary, the most frequent detected aberration
using FISH was monosomy 22 followed by loss of
Table 1 Comparison of the chromosomal aberrations detected by fluorescence in situ hybridization in native tumor




FISH dapped slides FISH cell culture Cytogenetic
1p 22 9p 10 14 18 1p 22 9p 10 14 18 1p 22 9p 10 14 18 Additional
aberrations
T6801 15 1 1 0 - 0 1 1 1 0 - 1 1 0 1 0 0 0 1 0
T6805 7 0 1 0 - 0 0 0 1 0 - 0 0 0 1 0 0 1/2 0 1
T6815 13 1 1 0 - 1 0 0 0 0 - 1 0 0 1 0 0 0 0 0
T6821 11 0 0 0 - 0 0 0 0 0 - 0 0 0 0 0 0 0 0 0
T6849 18 0 0 0 - 0 0 0 0 0 - 0 0 - - - - - - -
T6852 25 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0
T6855 32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
T6856 17 0 0 0 0 1 1 0 0 0 0 0 0 - - - - - - -
T6857 13 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 1 1 1 1
T6858 38 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
T6860 21 - - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
T6861 21 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 1
T6863 15 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0
T6886 18 1 1 - - - - 1 1 0 0 0 0 0 1 0 0 0 0 1
T6889 31 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
T6894 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
T6922 9 0 0 1 0 0 0 0 0 1 0 0 0 - - - - - - -
T6926 13 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1
T6927 15 0 1 2 2 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0
T6930 18 1 0 0 0 0 0 1 0 0 0 0 0 - - - - - - -
T6934 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
T6940 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
17,95 5 10 2 1 3 2 4 9 1 0 2 1 0 7 0 2 2 2
0: normal/ 1: loss/ 2: gain/ - no results.
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tumor tissue as well as in the cell culture.
Comparison of karyotyping and FISH data
The comparison of karyotyping and FISH data presented
accordance to the greatest extent concerning the chro-
mosomes 14, 18 and 22. The losses of chromosome re-
gions 1p and 9p were not detectable using conventional
karyotyping and the FISH showed no losses of chromo-
some 10 (Figure 1).
Comparison of FISH data from native and cultured
tumor cells
The comparison of FISH data from native and cultured
tumor cells showed an accordance of 93.4% (Figure 3).
Moreover, both native tumor tissue and cell culture
present a total of 83.5% inconspicuous karyotype and
16.5% aberrations. In a total of four FISH examinations
(3.3%), chromosomal aberrations were found in native
tumor tissue but not in the primary tumor cell culture.Conversely, there were chromosomal aberrations in the
primary tumor cell culture which was not shown in the
native tumor tissue in four other examinations (3.3%). An
explanation for the changes is the use of different native
tumor tissue fragments.
Discussion
Clinical and genetic background
Most of the meningiomas classified as WHO grade I be-
have in a benign fashion as predicted by their histology:
patients who are treated by complete surgical resection
are usually cured and remain free of tumor recurrence.
But grade I meningiomas may also present with grossly in-
vasive tumor recurrence [11,34]. On the other hand, a
complete surgical removal, the most important factor in
preventing recurrence, is sometimes hard to achieve, as
severe neurological impairment must be avoided, and even
some completely resected tumors recur.
Actually, a main objective of meningioma research is to
detect these meningiomas and to find predictive marker
Figure 1 Number of chromosomal aberrations in primary cell culture versus native tumor tissue detected using fluorescence
in situ hybridization and karyotyping (22 cases analyzed).
Figure 2 Representative pictures of meningioma primary
culture cells using fluorescence in situ hybridization with
probes (A/B: CL 1p36/22q11, C/D: CL 9p21/10q23, E/F: CL
14q24/18q21) from MetaSystems GmbH. A/C/E: normal cells.
B: monosomy 22 in comparison with loss of 1p. D: loss of 9p.
F: monosomy 14.
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reported. The most reliable marker is loss of chromosome
22 and the most promising prognostic marker is loss of
chromosome region 1p. Recent studies have shown that
meningiomas are cytogenetically heterogeneous tumors
which frequently display complex karyotypes (more than
three numerical or structural aberrations) [3-20]. There-
fore a better treatment and advice of meningioma patients
after neurosurgical procedures may be possible using a
fast and reliable genetic diagnostic tool. Since now, there
is no established method to detect typical genetic findings
in meningiomas in the daily routine for the surgeon which
would provide a fast and valid result.
Karyotyping and FISH
In the presented study, we analysed 22 meningiomas
by conventional karyotyping and FISH analysis. Both
methods were compared and evaluated. The examin-
ation with FISH showed - as expected based of recent
reports [1,2,35-37] - monosomy 22 as the most frequent
aberration. The second most frequent aberration was
the loss of the chromosome region 1p followed by the
loss of chromosome 14. Furthermore there were numer-
ical and structural aberrations of the chromosomes 9, 10
and 18 in some cases. Our results showed much more
chromosomal losses than gains in comparison to a study
of Sayagués and colleagues [16]. Chromosomal gains
were detected in the native tumor tissue using FISH in
one case (4.5%) but not in cell culture. Using conven-
tional karyotyping the cell culture presented gains of
chromosomes in three cases (13.6%). The other aberra-
tions in the cell culture were chromosomal losses.
The karyotyping and FISH data show accordance to the
greatest possible extent concerning the chromosomes 14,
18 and 22. The losses of chromosome regions 1p and 9p,
which were detected using FISH, were not observed using
karyotyping. One possible reason is the evaluation of 200
cell nuclei for FISH analysis in comparison to maximal 10
metaphases for karyotyping. For such evidence the FISHanalysis is the most sensitive method. Particularly in view
of progression associated marker the losses of 1p and 9p
are important for the clinical application to recognize the
patients with the high risk of tumor recurrence.
Generally the loss of chromosome 10 is a typical but rare
event in meningiomas. In the present study no statement is
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analysis is necessary.
Due to unsuitable tissue or insufficient fixation, in 4.5%
of the examinations of native tumor tissues, FISH was not
successful and the evaluation of 200 cell nuclei required
for statistical analysis was not always ensured. Further-
more the autofluorescence complicated the analysis and
extended the time to count the signals in the cell nuclei.
There was a chromosomal aberration in the native
tumor tissue which was not detected in the cell culture
in a total of four FISH examinations. Conversely, in four
other examinations, there were chromosomal aberra-
tions in the cell culture which were not shown in the
native tumor tissue. Thereby we should notice that even
if the FISH analysis is a well established method never-
theless an agreement of 100% cannot be achieved be-
cause of the use of heterogeneous biological material
and different preparation techniques. The advantages of
the native tumor tissue preparations were the use of na-
tive biological material and the avoidance of time-
consuming and expensive cell culture preparation. The
disadvantage was that the preparation quality was not as
good as the cell culture preparation. The advantages of
the cell culture preparations were the isolated cell nuclei
on the object slides, the particularly clear FISH signals,
and the easy and the fast analysis of 200 cell nuclei. The
disadvantages of the cell culture preparations were the
time-consuming primary culture and the possibility that
the primary culture may show no growth.
Clinical application
The raised data reveal that both methods can be used for a
valid analysis of chromosome aberrations on meningiomas
and allows the following proposal: For the clinical diagno-
sis, native tumor tissue preparations will be prepared, and
the FISH investigations can be performed immediately. In
laboratories with special equipment for cell culture, pri-
mary tumor cells can be cultured additionally. The cultiva-
tion takes place until the primary culture shows a closedFigure 3 Comparison of chromosomal aberrations between native tu
in situ hybridization.cell layer. This takes 17.95 days in average, according to
our experience. Then the cells will be dispersed and cell
culture preparations will be made. After three days the
FISH can take place. If there is no primary cell culture
available, the FISH analysis of the native tumor tissue
preparations is sufficient due to the presented data. Fur-
thermore the possibility consist to isolate DNA, RNA or
proteins from the primary culture or to perform immu-
nostainings. Thus a reliable diagnostic tool is nearly guar-
anteed for the patients.
The development of an easy and credible method for
chromosomal analysis in meningiomas is important for
the translational import in clinical routine. Only if we
are able to establish a method into the clinical routine
without much more effort, we will have a benefit for the
patients in the future. In the presented work, we pre-
sented for the first time a reliable and smart method to
analyse the prognostically important chromosomal aber-
rations in meninigomas. The introduction of the FISH
diagnostics in meningiomas will influence the postopera-
tive management of this patient collective in future.
Conclusions
In conclusion, the analysis of chromosomal aberrations
in meningiomas based on FISH delivers fast and signifi-
cant results. The study demonstrates the high sensitivity
and specificity of FISH for detecting chromosomal and
genetic abnormalities specific to meningioma cell cul-
tures and tissue.
A recommendation for routine use of FISH based ana-
lysis is displayed in Figure 4. During the operation the
dapped slides should be prepared, and the FISH investi-
gations can be performed in the laboratory immediately.
The use of probes 1p36 and 22q11 is sufficient because
loss of chromosome 22 is a typical general marker for
meningiomas, and loss of chromosome region 1p is the
most distinctive prognostic marker. According to the re-
sult of FISH analysis, the laboratory informs the neurosur-
geon about the risk level of meningioma, which allows formor tissue and primary cell culture using fluorescence
Figure 4 The workflow of the cytogenetic diagnostic in clinical practice.
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ule. Meningioma patients with loss of chromosome region
1p will receive close-mesh follow up and will receive early
treatment if the tumor recurs.
FISH is therefore a useful adjunct to histopathology for
analyzing fresh tissue or cell culture. The results of the
FISH analysis allow a classification of the patients into a
suitable follow-up and an early treatment of high risk
meningiomas. The results of the FISH analysis are as reli-
able as other cytogenetic methods for clinical routine, but
quicker and cheaper. In the future, the FISH analysis
should be tested in a large cohort of meningioma patients
to validate and establish this molecular biological tool.
Methods
Patient population
A study on 22 meningiomas of patients [male 4/female
18] operated at the Department of Neurosurgery, Saarland
University was performed. The average patient age was
57.7 years. The 22 meningiomas comprised 16 tumors of
WHO grade I, 5 tumors of WHO grade II and 1 tumor of
WHO grade III (Table 2).Table 2 Correlation between clinical variables and WHO tumo
Total WHO g
Number of patients (%) 22 16 (72
Age in years Ø 57,7 Ø 5
Gender (females/males) 18/4 13/
Localisation (%)
Convexity 12 (54,5) 8 (36
Skull base 10 (45,5) 8 (36
Spinal 0 (0) 0 (Cell culture and preparation
From each meningioma, fragments of the tumor were
placed in Dulbecco’s Modified Eagle Medium (GIBCO®)
with 1% penicillin/streptomycin immediately after surgery.
In the neurooncological laboratory one tumor fragment
was used for a primary culture. For that, the tumor sample
was minced with a scalpel and small scissors. The cells
were suspended in Dulbecco’s Modified Eagle Medium
containing 10% fetal calf serum, 1% non-essential amino
acids and 1% penicillin/streptomycin, and were distributed
into 25 cm3 cell culture flasks. The incubation of the pri-
mary cultures took place at 37°C with 5% CO2 in air,
whereby the medium was changed twice per week. The
chromosome preparations and Giemsa banding were
performed according to standard procedures [38]. The
Software IKAROS (Metasystems GmbH, Altlussheim,
Germany) was used to generate the karyotypes.
For FISH analysis the primary tumor cells were dispersed
with 0.05% Trypsin-EDTA (GIBCO®). The dispersed cells
were suspended by centrifugation at 1000 rpm for 8 mi-
nutes. After this, the supernatant was discarded and the
pellet was treated with 0.075 M KCl solution. The cellr grade in meningiomas
rade I WHO grade II WHO grade III
,73) 5 (22,73) 1 (4,54)
9,4 Ø 56,2 Ø 38,0
3 5/0 0/1
,4) 3 (13,6) 1 (4,5)
,4) 2 (9,1) 0 (0)
0) 0 (0) 0 (0)
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The supernatant was once again discarded and the cells
were fixed with fixative (methanol/acetic acid, 3:1) for one
hour. After fixation the cell suspension was dropped onto
object slides.
Preparation of dapped slides
In addition to cell culture, one tumor fragment was used
for the preparation of dapped slides. Therefore a fragment
of the tumor was dabbed onto object slides coated with si-
lane and was fixed with DeLauney fixative (acetone/etha-
nol, 1:1, with 0.05% trichloroacetic acid). The storage was
made at −20°C.
Fluorescence in situ hybridization
Tissue specimens from tumors were obtained freshly after
surgery and dabbed on microscope slides for FISH ana-
lysis. The slides were treated with RNase A for thirty mi-
nutes at 37°C and placed three times in 2xSSC for five
minutes at room temperature (RT). Cells were digested in
100 ml 0.01 M HCl with 10 mg pepsin (Serva) 0,7 mA for
1 min and 45 sec at 37°C. Slides were dipped in 1xPBS for
5 min, 4%PFA/1×PBS for 10 min for fixation and 1xPBS
for 5 min. They were then dehydrated in 70%, 80%, 95%
ethanol and air-dried. Dual-probe hybridization was per-
formed using locus-specific probes for 1p36, 9p21, 10q23,
14q24, 18q21 and 22q11 which were generated by Meta-
systems GmbH (Altlussheim, Germany). Then probes
were pipetted on slides and denatured for 2 minutes at
75°C with the target. Afterwards, they were incubated
overnight at 37°C in a humidified chamber. Stringency
washes were performed in 0.4×SSC for 2 minutes at
72°C and 2×SSC/0.05% Tween-20 for 30 sec at RT. Fi-
nally, slides were counterstained with DAPI antifade
(Vectashield, Vector Laboratories).
At least 200 non-overlapping nuclei per sample were
counted for evaluation according to the Hopman cri-
teria [39], using an Olympus AX70 fluorescence micro-
scope. Cut-offs for alterations were determined by
comparison with normal human lymphocytes as control
samples at 10% for deletions of 1p36, 9p21, 10q23, 14q24,
18q21 and 22q11.
Ethical approval
Written informed consent was obtained from each pa-
tient participating in the study. We have a positive vote
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